A Case of Pustular Psoriasis Developed during Infliximab Treatment for Crohn's Disease.
- Author:
Jin Yong KIM
1
;
Mira CHOI
;
Kwang Hyun CHO
Author Information
1. Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea. khcho@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Infliximab;
Pustular psoriasis;
TNF-alpha inhibitor
- MeSH:
Adolescent;
Antibodies, Monoclonal;
Arthritis, Rheumatoid;
Biopsy;
Crohn Disease;
Dermatitis;
Follow-Up Studies;
Humans;
Hyperpigmentation;
Psoriasis;
Recurrence;
Skin;
Tumor Necrosis Factor-alpha;
Infliximab
- From:Korean Journal of Dermatology
2012;50(9):810-813
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Infliximab is a monoclonal antibody that binds and inactivates tumor necrosis factor-alpha. It has been successfully used to manage diseases associated with a Th1 profile such as psoriasis, Crohn's disease, and rheumatoid arthritis. A 15-year-old boy presented for erythematous scaly papules and pustules with crust on his entire body, which had appeared initially 2 months ago. He had been treated with infliximab for Crohn's disease during the last 14 months and had not been diagnosed with psoriasis. A skin biopsy specimen demonstrated papulosquamous dermatitis with subcorneal pustule formation, suggestive of pustular psoriasis. The patient was treated with oral retinoid 20 mg/d for 3 weeks and 10 mg/d for next 3 weeks with concurrent topical steroid, and most lesions disappeared completely with post inflammatory hyperpigmentation. No evidence of recurrence has been observed during 3 months of followup.
